Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Devlin

Showing results (31-40 of 80) with videos related to

Pageof 8
Sort By:
Bone Marrow Transplantation|January 31, 2023
EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantationMiriam Sanchez-Escamilla, Jessica Flynn, Sean Devlin, et al.
Transplantation and Cellular Therapy|September 20, 2024
Establishing a Graft-Versus-Host Disease (GVHD)-Focused Multidisciplinary Telehealth ClinicAndrew C Harris, Alina Markova, Sean Devlin, et al.
NEJM Evidence|February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell LeukemiaJae H Park, Sean Devlin, Benjamin H Durham, et al.
Blood Advances|April 12, 2021
Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AMLBrian C Shaffer, Jean-Benoit Le Luduec, Soo Park, et al.
Bone Marrow Transplantation|January 16, 2020
Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipientsKathryn T Maples, Molly Maloy, Sean Devlin, et al.
Scientific Reports|March 2, 2021
Oncologic immunomodulatory agents in patients with cancer and COVID-19Justin Jee, Aaron J Stonestrom, Sean Devlin, et al.
Blood Advances|March 1, 2024
Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantationWarren B Fingrut, Eric Davis, Anne Archer, et al.
Transplantation and Cellular Therapy|October 3, 2023
Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell TransplantationKarthik Nath, Kristen Peterson, Samantha Brown, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
Bone Marrow Transplantation|April 28, 2022
CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosisMariam T Nawas, Jeong-Ok Lee, Jessica Flynn, et al.
Pageof 8

Showing results (31-40 of 80) with videos related to

Sort By:
Pageof 8
Bone Marrow Transplantation|January 31, 2023
EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantationMiriam Sanchez-Escamilla, Jessica Flynn, Sean Devlin, et al.
Transplantation and Cellular Therapy|September 20, 2024
Establishing a Graft-Versus-Host Disease (GVHD)-Focused Multidisciplinary Telehealth ClinicAndrew C Harris, Alina Markova, Sean Devlin, et al.
NEJM Evidence|February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell LeukemiaJae H Park, Sean Devlin, Benjamin H Durham, et al.
Blood Advances|April 12, 2021
Prospective KIR genotype evaluation of hematopoietic cell donors is feasible with potential to benefit patients with AMLBrian C Shaffer, Jean-Benoit Le Luduec, Soo Park, et al.
Bone Marrow Transplantation|January 16, 2020
Lack of a significant pharmacokinetic interaction between letermovir and calcineurin inhibitors in allogeneic HCT recipientsKathryn T Maples, Molly Maloy, Sean Devlin, et al.
Scientific Reports|March 2, 2021
Oncologic immunomodulatory agents in patients with cancer and COVID-19Justin Jee, Aaron J Stonestrom, Sean Devlin, et al.
Blood Advances|March 1, 2024
Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantationWarren B Fingrut, Eric Davis, Anne Archer, et al.
Transplantation and Cellular Therapy|October 3, 2023
Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell TransplantationKarthik Nath, Kristen Peterson, Samantha Brown, et al.
Leukemia & Lymphoma|June 1, 2022
Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approachOscar B Lahoud, Heather Landau, James Nguyen, et al.
Bone Marrow Transplantation|April 28, 2022
CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosisMariam T Nawas, Jeong-Ok Lee, Jessica Flynn, et al.
Pageof 8